Breaking News

Tweet TWEET

MELA Sciences, a Leader in the Fight Against Melanoma, to Release Third Quarter 2013 Financial Results and Host Conference Call

MELA Sciences, a Leader in the Fight Against Melanoma, to Release Third
Quarter 2013 Financial Results and Host Conference Call on Wednesday, November
6, 2013

IRVINGTON, N.Y., Oct. 14, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind^®, the first and only FDA approved optical diagnostic
device for melanoma detection used by dermatologists in their fight against
melanoma, today announced that it will release its 2013 third quarter
financial results after the close of trading on Wednesday, November 6, 2013.
MELA Sciences' executives will also host a conference call that day at 4:30 PM
ET to discuss the results, as well as provide a general business update.

Date:                 Wednesday, November 6, 2013
Time:                 4:30 PM ET
                     
To participate in the teleconference, please dial:
Domestic toll-free:   (877) 303-9205
International:        (760) 536-5226

To listen via live webcast, please go to the investor relations section of the
MELA Sciences' website at http://www.melasciences.com approximately 10 minutes
prior to the teleconference start time. If you are unable to participate
during the live conference call and webcast, the conference call webcast will
be archived and available for replay for approximately 90 days.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind^®, and its further design and development.
MelaFind is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind
has been approved by the US Food and Drug Administration for use in the US. In
addition, MelaFind has received CE Mark approval and is approved for use in
the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

CONTACT: For further information contact:

         For Investors
         Lynn Pieper
         Westwicke Partners
         415-202-5678
        
         For Media
         Erica Sperling
         Rpr Marketing Communications
         212.317.1462
         erica.sperling@rprmc.com
 
Press spacebar to pause and continue. Press esc to stop.